ciclesonide

06/01/2001 - "Ciclesonide significantly improved asthma control. "
05/01/2012 - "Clinical efficacy studies suggest that Ciclesonide is superior to placebo and is at least as effective as several active comparators with an improved therapeutic margin thereby improving the therapeutic outcome in patients of asthma."
01/01/2008 - "Lots of clinical trials show that ciclesonide is effective in asthma control in a wide range of doses from 40 do 1280 mug/day in a dose-dependent manner. "
11/01/2019 - "Inhaled ciclesonide is an effective treatment for horses with equine asthma. "
01/01/2008 - "Inhaled ciclesonide delivered by HFA-MDI is effective in the prophylactic treatment of persistent asthma in adults, adolescents and children, and is generally well tolerated. "

07/01/2022 - "To assess the efficacy of inhaled ciclesonide in reducing the risk of adverse outcomes in COVID-19 outpatients at risk of developing severe illness. "
01/01/2022 - "Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial."
01/01/2023 - "Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19)."
11/20/2022 - "Impact of inhaled ciclesonide on asymptomatic or mild COVID-19: A randomized trial."
09/28/2022 - "The successful management of patients infected with coronavirus disease 2019 (COVID-19) with inhaled ciclesonide has been reported, however few studies have investigated its application among hospitalized patients. "

11/20/2022 - "The risk ratio (RR) was 2.08 (95% confidence interval (CI): 1.15-3.75), indicating a worsening of pneumonia in the ciclesonide group. "
12/31/2020 - "Primary endpoint analysis will be performed using the Fisher exact test to determine statistically significant differences in the pneumonia exacerbation rate between the ciclesonide and symptomatic treatment groups. "
12/01/2020 - "The lymphocyte count after ciclesonide treatment in the non-severe pneumonia group was significantly higher (p = 0. "
11/20/2022 - "The aim of this study was to determine the efficacy and safety of ciclesonide in the treatment of novel coronavirus disease 2019 (COVID-19) as gauged by pneumonia progression. "
11/20/2022 - "The current results indicated that ciclesonide exacerbates signs of pneumonia on images in individuals with mild or asymptomatic symptoms of COVID-19 without worsening clinical symptoms."

12/01/2017 - "The mice were grouped into 4 groups: control group, allergic rhinitis (AR) group, ciclesonide (CIC) group, and PPC group. "
11/30/2008 - "Therefore the place of ciclesonide in the treatment of allergic rhinitis relative to other existing products remains unclear."
11/30/2008 - "Intranasal ciclesonide for allergic rhinitis."
05/05/2008 - "Ciclesonide (Omaris) for allergic rhinitis."
04/01/2008 - "New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide."

12/01/2021 - "Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks."
07/01/2006 - "Ciclesonide has also been shown to improve lung function, to treat the underlying inflammation, to be effective as monotherapy in patients with persistent asthma, to have reduced side effects compared with other ICS, and to be easy to use with once-daily dosing. "
04/01/2009 - "Evaluation of a study assessing the short-term effects of ciclesonide on small airways inflammation in patients with mild to moderate asthma. "
03/01/2016 - "Once-daily generic ciclesonide (80 μg or 160 μg), for 12 weeks, is effective to improve airway inflammation and asthma control in atopic children with persistent asthma."
05/01/2005 - "Ciclesonide potently inhibited chronic allergic inflammation, remodeling, and BHR without having an effect on body weight and the hypothalamic-pituitary-adrenal axis. "